Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at a public offering price of $4.70 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of common stock at a public offering price of$4.6999 pe ...